4 hours ago
1
koto_feja/E+ via Getty Images
I-Mab (NASDAQ:IMAB) said on Monday that it is accelerating investment in its lead drug candidate, givastomig, a bispecific antibody for cancer treatment.
The company plans to launch a global phase 2 trial and expand its ongoing phase 1b study with
© FBT Company 2025. All rights are reserved
English (US) ·